Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1719-1723

  Mylonas, Ioannis ^a,b   Makovitzky, Josef ^b   Jeschke, Udo ^a,b   Briese, Volker ^b   Friese, Klaus ^a,b   Gerber, Bernd ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Breast cancer; DCIS; Her2 neu; Ki67; p53; Steroid receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CARCINOMA IN SITU; CELL INTERACTION; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DUCTAL CARCINOMA IN SITU; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE MAMMARY DUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21244445023     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Gerber B, Muller H, Reimer T, Krause A and Friese K: Nutrition and lifestyle factors on the risk of developing breast cancer. Breast Cancer Res Treat 79: 265-276, 2003.
2. Gerber B and Mylonas I: Reduction of the risk of breast cancer. Zentralbl Gynaekol 125: 6-16, 2003.
3. Swenson KK, Decher L, Haselow R, Farrell JB and Sperduto PW: Prognostic factors after conservative surgery and radiation therapy for early stage breast cancer. Am J Clin Oncol 21: 111-116, 1998.
4. Gerber B: Premalignant lesions - Current assessment of the clinical utility of ADH, LCIS and DCIS. Geburtshilfe Und Frauenheilkunde 63: 271-272, 2003.
5. Ernster VL, Barclay J, Kerlikowske K, Wilkie H and Ballard-Barbash R: Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160: 953-958, 2000.
6. Lakhani SR: The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 187: 272-278, 1999.
7. Menard S, Fortis S, Castiglioni F, Agresti R and Balsari A: HER2 as a prognostic factor in breast cancer. Oncology 61: 67-72, 2001.
8. Bernoux A, de Cremoux P, Laine-Bidron C, Martin EC, Asselain B and Magdelenat H: Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 49: 219-225, 1998.
9. Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 57: 227-238, 1998.
10. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O and Nusse R: Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239-1245, 1988.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
12. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P and Dogliotti L: Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105-3110, 1996.
13. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE and Westley BR: Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5: 2682-2688, 1999.
14. Levesque MA, Yu H, Clark GM and Diamandis EP: Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. J Clin Oncol 16: 2641-2650, 1998.
15. Rohan TE, Hartwick W, Miller AB and Kandel RA: Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 90: 1262-1269, 1998.
16. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V and Friese K: Immunohistochemical expression of the tumour marker CA-125 in normal, hyperplastic and malignant endometrial tissue. Anticancer Res 23: 1075-1080, 2003.
17. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V and Friese K: Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Acta Histochem 705: 245-252, 2003.
18. Mylonas I, Jeschke U, Shabani N, Kuhn C, Balle A, Kriegel S, Kupka MS and Friese K: Immunohistochemical analysis of estrogen receptor alpha (ER-a), estrogen receptor beta (ER-b) and progesterone receptor (PR) in normal human endometrium. Acta Histochem 106: 245-252, 2004.
19. Remmele W and Stegner HE: Vorschlag zur einheitlichen Definierung eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8: 138-140, 1987.
20. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992.
21. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ and Millis RR: Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 28: 644-648, 1992.
22. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ 3rd, Liu ET and Conway K: HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 18: 267-274, 2000.
23. Schimmelpenning H, Eriksson ET, Falkmer UG, Azavedo E, Svane G and Auer GU: Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Virchows Arch A Pathol Anat Histopathol 420: 433-440, 1992.
24. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA and Preisler HD: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 52: 2597-2602, 1992.
25. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC and McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23: 974-979, 1992.
26. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW and Nicholson RI: Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943-947, 1989.
27. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM and Syrjanen K: The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122: 687-692, 1996.
28. Hoque A, Menter DG, Sahin AA, Sneige N and Lippman SM: No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 10: 153-154, 2001.
29. Bosari S, Lee AK, Viale G, Heatley GJ and Coggi G: Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A Pathol Anat Histopathol 421: 291-295, 1992.
30. Gunther T, Schneider-Stock R, Rys J, Niezabitowski A and Roessner A: p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. J Cancer Res Clin Oncol 123: 388-394, 1997.
31. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S and Iwase H: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6: R24-30, 2004.